GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » EV-to-EBIT

Bio-Rad Laboratories (Bio-Rad Laboratories) EV-to-EBIT

: -10.41 (As of Today)
View and export this data going back to 1999. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bio-Rad Laboratories's Enterprise Value is $8,336 Mil. Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-801 Mil. Therefore, Bio-Rad Laboratories's EV-to-EBIT for today is -10.41.

The historical rank and industry rank for Bio-Rad Laboratories's EV-to-EBIT or its related term are showing as below:

BIO.B' s EV-to-EBIT Range Over the Past 10 Years
Min: -81.66   Med: 11.37   Max: 173.4
Current: -9.75

During the past 13 years, the highest EV-to-EBIT of Bio-Rad Laboratories was 173.40. The lowest was -81.66. And the median was 11.37.

BIO.B's EV-to-EBIT is ranked worse than
100% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.21 vs BIO.B: -9.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bio-Rad Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $8,943 Mil. Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-801 Mil. Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.95%.


Bio-Rad Laboratories EV-to-EBIT Historical Data

The historical data trend for Bio-Rad Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 3.37 4.03 -2.58 -11.25

Bio-Rad Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 -66.89 -22.09 -72.90 -11.25

Competitive Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBIT falls into.



Bio-Rad Laboratories EV-to-EBIT Calculation

Bio-Rad Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8336.198/-800.665
=-10.41

Bio-Rad Laboratories's current Enterprise Value is $8,336 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-801 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories  (NYSE:BIO.B) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-800.665/8942.72596
=-8.95 %

Bio-Rad Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $8,943 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-801 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.